bims-imseme Biomed News
on Immunosenescence and T cell metabolism
Issue of 2026–11–22
forty-two papers selected by
Pierpaolo Ginefra, Ludwig Institute for Cancer Research



  1. Res Sq. 2026 Nov 10. pii: rs.3.rs-10375256. [Epub ahead of print]
      Checkpoint-responsive exhausted CD8 + T cells sustain immunity during chronic infection and cancer, but the tissue-derived signals that preserve these cells remain poorly defined. Here, we identify extracellular ATP sensing through P2RX7 as a microenvironmental circuit that maintains progenitor exhausted (T PEX ) and tissue-resident exhausted (TR TEX ) CD8 + T cells. P2RX7 was enriched in T PEX and TR TEX cells and was required cell-intrinsically to preserve their abundance, diversity, and developmental competence during chronic viral infection. Loss of P2RX7 restricted early progenitor trajectories and induced mitochondrial dysfunction, lipid peroxidation, and terminal exhaustion-associated phenotypes. Mechanistically, P2RX7-dependent Ca 2+ influx activated NFAT/AP-1 signaling, which induced KLF3 to promote mitochondrial fitness, subset development, and persistence of T PEX and TR TEX cells. P2RX7 also supported CD8 + T cell expansion after PD-1 blockade, whereas pharmacologic P2RX7 activation enhanced antitumor immunity in preclinical models. These findings define an extracellular ATP-P2RX7-KLF3 program that couples tissue damage sensing to metabolic adaptation and persistence of checkpoint-responsive exhausted CD8 + T cells.
    DOI:  https://doi.org/10.21203/rs.3.rs-10375256/v1
  2. Sci Immunol. 2026 Nov 20. 11(125): eaej5412
      Aging profoundly alters CD8 T cells, driving senescence and exhaustion that contribute to immune decline. By mapping chromatin accessibility across functional and dysfunctional CD8 T cell subsets from young and aged mice, we found that age-related CD8 T cell dysfunction was associated with a loss of regulation at three distinct levels. Dysfunctional CD8 T cells showed reduced accessibility of genes essential for "stemness," indicating diminished regenerative potential. Exhausted memory T cells (Tmem cells) showed decreased accessibility of "restraint" genes, which limit differentiation postactivation. Last, both senescent virtual memory T cells (TVM cells) and exhausted Tmem cells displayed increased accessibility of "terminal inhibitory" genes, underscoring progression toward irreversible dysfunction. The inhibitory receptor gene Fcgr2b, encoding FcγRIIb/CD32b, was notably increased in a subset of aged TVM cells with regulatory characteristics. This study defines mechanisms of CD8 T cell aging and identifies a CD8 regulatory T cell (Treg cell) population that emerges as a hallmark of aging.
    DOI:  https://doi.org/10.1126/sciimmunol.aej5412
  3. Int Immunopharmacol. 2026 Nov 14. pii: S1567-5769(26)01521-3. [Epub ahead of print]191(Pt 2): 117673
       BACKGROUND: Immune aging is characterized by impaired immune memory, manifested as increased susceptibility to previously encountered pathogens and reduced vaccine efficacy, yet the underlying mechanisms remain incompletely understood. Here, we investigated whether age-related RHOA hyperactivation, together with reduced migratory persistence, skews the fate decision of CD8+ T cells away from memory commitment toward terminal effector differentiation.
    METHODS: Naïve CD8+ T cells were isolated from peripheral blood of young and older healthy donors. Clustering capacity and migratory persistence were assessed by Incucyte live-cell imaging and single-cell trajectory tracking. Differentiation phenotypes were analyzed by flow cytometry. Single-cell RNA sequencing and module scoring were performed to identify key molecular pathways, with validation by Western blotting. Pharmacological inhibition of RHOA-ROCK pathway and mechanical cluster disruption were used to establish causal relationships.
    RESULTS: In qualitative assays, Aged CD8+ T cells formed fewer activation-induced clusters in vitro and displayed reduced migratory persistence relative to young cells. Flow cytometry revealed accelerated effector differentiation in aged CD8+ T cells, accompanied by diminished memory commitment. Single-cell RNA sequencing uncovered a transcriptional signature consistent with RHOA hyperactivation, together with elevated senescence-associated secretory phenotype (SASP) and exhaustion signatures and dysregulated cytoskeletal dynamics. Biochemical assays confirmed elevated RHOA activity (GTP-bound RHOA) and sustained cofilin phosphorylation, the latter indicating cofilin inactivation and impaired actin depolymerization. GSEA showed enrichment of mTORC1 signaling and concomitant suppression of WNT/β-catenin signaling in aged CD8+ T cells, consistent with a cell-fate bias toward terminal effector differentiation at the expense of memory commitment. Importantly, pharmacological inhibition of RHOA-ROCK pathway restored CD62L and CD127 expression in aged CD8+ T cells, consistent with at least partial restoration of an effector-associated phenotype.
    CONCLUSION: In aged CD8+ T cells, RHOA hyperactivation impairs cofilin-mediated actin depolymerization, compromising activation-induced clustering and sustaining mTORC1 signaling while repressing WNT/β-catenin-dependent memory programs, thereby skewing differentiation toward a terminal effector fate. Pharmacological inhibition of RHOA-ROCK pathway partially reverses these alterations, suggesting that this pathway may represent a potential therapeutic target for counteracting CD8+ T cell immune aging.
    Keywords:  Cofilin; Migratory persistence; RHOA; T cell aging; T cell memory
    DOI:  https://doi.org/10.1016/j.intimp.2026.117673
  4. J Exp Med. 2026 Dec 07. pii: e20261316. [Epub ahead of print]223(12):
      The liver constitutes a distinct immunological niche in which CD8+ T cells balance immune protection and tissue integrity. How chronic liver disease (CLD) remodels human liver-resident CD8+ T cells remains poorly understood. We demonstrate that activated hepatic stellate cells (HSCs) create immunoinstructive fibrotic niches that regulate liver-resident CD8+ T cell differentiation, localization, and function. CD103-expressing liver-resident CD8+ T cells accumulate with increasing fibrosis severity and preferentially localize within collagen-rich scar tissue. HSC-derived and matrix-retained TGFβ promote acquisition of a residency program characterized by upregulation of CD103, ECM-binding integrins, and adhesion molecules. Despite their increased abundance, liver-resident CD8+ T cells in CLD exhibit impaired antigen-dependent effector function, increased inhibitory receptor expression, and a transcriptional program associated with T cell dysfunction. Importantly, responses to PMA/ionomycin remain intact, indicating preserved effector competence. Mechanistically, HSCs directly suppress antigen-specific liver-resident CD8+ T cell function, with partial restoration following PD-L1/PD-L2 blockade. These findings identify the fibrotic niche as a central regulator of liver-resident CD8+ T cells and reveal how fibrosis can limit local immunosurveillance.
    DOI:  https://doi.org/10.1084/jem.20261316
  5. J Immunother Cancer. 2026 Nov 19. pii: e015140. [Epub ahead of print]14(11):
      
    Keywords:  Cytokine; Immune Checkpoint Inhibitor; T cell; Tumor Microenvironment
    DOI:  https://doi.org/10.1136/jitc-2026-015140
  6. J Immunol. 2026 Nov 02. pii: vkag315. [Epub ahead of print]215(11):
      CD8+ T cells are central mediators of adaptive immunity that eliminate infected cells and establish long-term immunological memory. Upon antigen encounter, naïve CD8+ T cells undergo rapid clonal expansion and differentiate into diverse effector and memory populations shaped by antigenic and inflammatory cues. Rather than following a single fixed pathway, this differentiation is increasingly recognized as a flexible and dynamic program that generates heterogeneous subsets with distinct functional and developmental potentials. CD8+ T-cell fate decisions are governed by the integration of multiple factors, including T-cell receptor signal strength, antigen exposure history, inflammatory cues, tissue context, host-specific factors, and antigen persistence, collectively driving the diversification of memory CD8+ T-cell populations. This review discusses current concepts in CD8+ T-cell differentiation, with a particular focus on the emergence, diversification, and functional heterogeneity of memory CD8+ T-cell subsets.
    Keywords:  CD8+ T cell; differentiation; heterogeneity; memory cells
    DOI:  https://doi.org/10.1093/jimmun/vkag315
  7. J Transl Med. 2026 Aug 26. pii: 1449. [Epub ahead of print]24(1):
       BACKGROUND: Chimeric antigen receptor (CAR)-T cell therapy has emerged as a transformative treatment for hematologic malignancies; however, its long-term efficacy is severely limited by poor cell persistence. CAR-T cell exhaustion has been recognized as a core factor limiting its persistence. Although multiple factors contribute to CAR-T cell exhaustion, recent studies have highlighted metabolic reprogramming as a particularly important and therapeutically actionable contributor.
    MAIN BODY: This review focuses on the critical role of glucose metabolism in driving cellular exhaustion, with particular emphasis on how glucose metabolic disorders and mitochondrial dysfunction act as key contributors. Furthermore, we summarize four principal intervention strategies, including in vitro metabolic pretreatment, in vivo counteraction of tumor microenvironment (TME) metabolic stress, metabolism-related gene engineering, and optimization of CAR structures.
    CONCLUSIONS: Collectively, this review provides a framework linking glucose metabolism-driven exhaustion to actionable metabolic interventions, thereby offering potential directions for mitigating CAR-T cell exhaustion. Current clinical translation challenges include balancing persistence with effector function, controlling toxicity, and addressing metabolic heterogeneity. Future research should prioritize these bottlenecks by exploring high-potential strategies such as pharmacological interventions and CAR structural modifications, as well as developing personalized regimens tailored to metabolic profiles to enhance long-term efficacy.
    Keywords:  Chimeric antigen receptor (CAR)-T cell exhaustion; Glucose metabolism reprogramming; Mitochondrial dysfunction
    DOI:  https://doi.org/10.1186/s12967-026-08868-7
  8. Biomark Res. 2026 Nov 15. pii: 160. [Epub ahead of print]14(1):
      CD8⁺ T cells are central cytotoxic effectors of anti-tumor immunity, but tumor-infiltrating CD8⁺ populations are functionally heterogeneous and include tumor-reactive, dysfunctional, and bystander states. Although the past decade of cancer immunology has focused largely on how local interactions within the tumor microenvironment shape these states, clinical observations linking chronic stress, sleep disruption, endocrine comorbidity, and circadian timing to immune checkpoint inhibitor (ICI) outcomes indicate that CD8⁺ T cell function is also modulated far beyond the tumor itself. In this review we adopt a whole-organism perspective to examine how autonomic and sensory neural circuits and the endocrine system act across anatomical compartments to govern CD8⁺ T cell priming, trafficking, metabolism, and exhaustion. We first analyze sympathetic, parasympathetic, and sensory neural axes as systemic effectors mediated by catecholamines, acetylcholine, neuropeptides, and brainstem-driven tone. We then examine endocrine regulation through the hypothalamic-pituitary-adrenal axis, metabolic hormones, and gonadal steroids. We integrate these axes within the tumor microenvironment, where nerve-derived signals, paracrine neuropeptides, and locally amplified glucocorticoid activity form a convergent suppressive network, and at the organismal level through stress amplification loops, sex dimorphism, gut-relayed microbial signaling, and circadian timing. Collectively, this evidence identifies neuro-endocrine signaling as an actionable, mechanistically stratified layer of systemic immune regulation and supports its evaluation as a source of biomarkers and pharmacological targets for sensitizing tumors to ICI therapy. This framework offered here is intended to bridge cancer neuroscience, endocrine oncology, and immunotherapy, and to define the criteria by which the next generation of systems-level immune sensitizers should be evaluated.
    Keywords:  CD8⁺ T cell exhaustion; Cancer neuroscience; Glucocorticoid receptor; Sexual dimorphism; Sympathetic nervous system; Systemic immunoregulation
    DOI:  https://doi.org/10.1186/s40364-026-01040-9
  9. J Extracell Vesicles. 2026 Nov;pii: e70384. [Epub ahead of print]15(11):
      Engineered biomimetic nanovesicle systems represent an emerging strategy for targeted immune modulation in cancer. In this study, we developed anti-CD8a-functionalized red blood cell membrane-derived nanovesicles (NVE) to selectively deliver the NFAT5 inhibitor KRN2 to CD8+ T cells. Transcriptomic and single-cell RNA sequencing analyses identified NFAT5 as a transcriptional regulator associated with PD-1 expression in highly exhausted CD8+ T cell subsets in cardia cancer. CD8a-NVE@KRN2 showed favourable physicochemical properties, efficient KRN2 loading, and preferential CD8+ T cell targeting. Functionally, targeted NFAT5 inhibition restored CD8+ T cell activity, promoted granzyme A-gasdermin B-mediated tumour cell pyroptosis, and indirectly shifted tumour-associated macrophages toward a more inflammatory, glycolysis-associated phenotype. In subcutaneous and orthotopic models, CD8a-NVE@KRN2 enhanced the antitumour effect of anti-PD-1 therapy. These findings support functionalized red blood cell membrane nanovesicles as a biomimetic platform for coordinated immune reprogramming in cancer.
    Keywords:  CD8+ T Cells; NFAT5; cardia cancer; pyroptosis; red blood cell membrane nanovesicles
    DOI:  https://doi.org/10.1002/jev2.70384
  10. J Clin Invest. 2026 Nov 19. pii: e207757. [Epub ahead of print]
      CD4⁺ T cells coordinate protective immunity against pathogens. However, how human CD4⁺ T cell memory is established and evolves following primary and repeated vaccinations remain incompletely understood. Using COVID-19 mRNA vaccination as a model, we tracked 50 distinct antigen-specific populations directly ex vivo with peptide-MHC class II tetramers in eight SARS-CoV-2-naïve individuals from pre-exposure baseline through memory time points after three mRNA doses. We showed that primary vaccination established the architecture of antigen-specific memory. Initial vaccination leveraged pre-existing memory while preferentially recruiting high-avidity T cells, establishing an immunodominance hierarchy dominated by a small subset of precursors. Booster vaccination refined both the magnitude and quality of T cell memory. It increased select populations and enhanced differentiation of subdominant CD4⁺ T cells. Populations that did not become more abundant after boosting retained their polyfunctional potential. Beyond establishing memory to the ancestral spike, vaccinations recruited cross-reactive T cells and increased the breadth of CD4+ T cell memory. Collectively, these findings reveal how human T cell memory evolves through sequential immunizations to generate a functionally diverse and broadly responsive memory repertoire against future viral challenges.
    Keywords:  Adaptive immunity; Immunology; Infectious disease; T cells; Vaccines
    DOI:  https://doi.org/10.1172/JCI207757
  11. Cell Commun Signal. 2026 Aug 22. pii: 616. [Epub ahead of print]24(1):
       BACKGROUND: CD8+ T lymphocytes are critical for rejecting cancer cells but often lose functionality in the immunosuppressive tumor microenvironment. Understanding this process could improve cancer immunotherapy. The enzyme GGPS1, which produces geranylgeranyl pyrophosphate (GGPP), has an unclear impact on CD8+ T cell cytotoxic function and tumor immune escape in clear cell renal cell carcinoma (ccRCC).
    METHODS: To investigate how GGPS1 deficiency in T cells affects tumor progression, we established Renca tumor models in mice with T-cell-specific deletion of GGPS1. A combination of approaches-including real-time PCR, western blotting, flow cytometry, in vitro cytotoxicity assays, Seahorse metabolic analysis, and measurements of glucose uptake and lactic acid secretion-was employed to dissect the role of GGPS1 in CD8⁺ T cell cytotoxicity and glycolysis. In parallel, adoptive transfer studies were conducted to evaluate the antitumor potential of CD8⁺ T cells engineered to overexpress GGPS1.
    RESULTS: CD8⁺ T cells isolated from ccRCC patients who failed to respond to PD-1 blockade exhibited markedly lower GGPS1 expression. In mice, T-cell-specific deletion of GGPS1 accelerated tumor growth, accompanied by diminished infiltration of cytotoxic CD8⁺ T cells and elevated expression of exhaustion markers-including PD-1, TIM-3, LAG-3, and TOX-on tumor-infiltrating CD8⁺ T cells. Silencing GGPS1 impaired cytokine production and antitumor activity, whereas restoring GGPS1 expression reinforced both functions. Notably, exogenous GGPP fully rescued the defects in cytotoxicity and glycolysis induced by GGPS1 knockdown. Mechanistically, GGPS1 promoted MEK/ERK signaling, and the MEK inhibitor trametinib abolished GGPP-driven enhancement of CD8⁺ T cell cytotoxicity and glycolysis. Finally, elevating GGPS1 levels in CD8⁺ T cells boosted the efficacy of both adoptive immunotherapy and immune checkpoint blockade in ccRCC models.
    CONCLUSIONS: These findings highlight the essential function of GGPS1 in regulating glycolysis and cytotoxicity in CD8+ T cells, offering potential therapeutic strategies for clinical tumor immunotherapy in ccRCC.
    Keywords:  GGPS1; Glycolysis; Immunotherapy; T cell
    DOI:  https://doi.org/10.1186/s12964-026-03167-6
  12. Sci Adv. 2026 Nov 20. 12(47): eaeh4461
      Immune protection against infections relies on long-term maintenance of a highly diversified naïve T cell repertoire. Transcription factors cooperate to enforce T cell metabolic quiescence and maintenance. However, less is known about the posttranscriptional networks that preserve naïve T cells. Here, we describe the RNA binding proteins T cell antigen 1 (TIA1) and TIA-like 1 (TIAL1) as key promoters of CD4 and CD8 T cell quiescence. T cells deficient in TIA1 and TIAL1 undergo premature T cell activation, exhaustion, and death in the absence of cognate antigens. Mechanistically, TIA1 and TIAL1 promote the messenger RNA translation of quiescence-associated transcription factors such as forkhead box P1, lymphoid enhancer factor 1, and T cell factor 1 to restrain homeostatic T cell proliferation and activation. In summary, our study highlights a previously unrecognized dependency on posttranscriptional gene regulation by TIA1 and TIAL1 for implementing the quiescent transcriptional programs for long survival of T cells.
    DOI:  https://doi.org/10.1126/sciadv.aeh4461
  13. Immunity. 2026 Nov 17. pii: S1074-7613(26)00441-3. [Epub ahead of print]
      Progenitor CD4+ T (Tpex) cells retain developmental plasticity and replenish antigen-specific CD4+ T cell responses in settings of chronic infection and cancer. Given the sustained, elevated expression of the transcription factor TOX across all CD4+ TEX cell subsets during chronic infection, we examined how TOX impacts CD4+ TEX differentiation during chronic infection. Deletion of TOX in lymphocytic choriomeningitis virus (LCMV)-specific transgenic CD4+ T cells impaired Tpex cell survival and drove unrestrained TEX cell differentiation. Multiomic profiling revealed that this effector-like state was concomitant with loss of TCF-1 pathway activity and gain of NFAT, NF-κB, and RUNX-coordinated transcriptional circuitry. TOX also promoted the multipotent potential of CD4+ Tpex cells to differentiate into T helper (Th)1-like or Tfh-like cells by day 8 post-infection (p.i.) prior to establishment of chronic infection. These data reveal a TOX-driven transcriptional network that maintains CD4+ Tpex cell function and persistence, supporting a durable and malleable response during persisting antigen stimulation.
    Keywords:  CD4(+) T cells; LCMV cl13; RUNX; TOX; chronic viral infection; effector T cells; exhaustion; progenitor T cells; single-cell genomics; transcriptional circuit
    DOI:  https://doi.org/10.1016/j.immuni.2026.10.015
  14. Geroscience. 2026 Nov 17.
      Older adults experience disproportionate morbidity and mortality from Clostridioides difficile infection (CDI); however, existing toxoid- and receptor binding domain (RBD)-based vaccines elicit suboptimal protection in aged hosts due to the age-associated defects in CD4+ T cell function, T follicular helper (TFH) cell activation, and antibody quality. We evaluated whether adenosine deaminase (ADA), an enzymatic immune modulator that degrades immunosuppressive adenosine, and improves GC TFH differentiation and survival, could reverse these age-related impairments when co-delivered with DNA vaccine plasmids targeting toxin A and B RBDs (pRBD). In aged mice, pRBD vaccination alone produced markedly reduced toxin-specific effector/memory CD4+ T cells, diminished TFH activation, and poor toxin A neutralization compared to vaccinated young mice. Co-immunization with plasmid-encoded adenosine deaminase-1 (pADA) restored toxin-specific CD4+ T cell generation and cytokine production, activation-induced marker (AIM) TFH responses, and antibody-mediate toxin neutralization to levels comparable to young adults. Mechanistically, pADA co-immunization was associated with the reduction of CXCR4 on germinal center (GC) TFH cells-a phenotype previously linked to impaired GC positioning and diminished B cell help in aging-suggesting that ADA may improve humoral quality through modulation of CXCR4 expression, a pathway previously associated with GC TFH positioning. These immune enhancements corresponded with improved clinical outcomes in morbidity, mortality, and weight loss following C. difficile spore challenge of aged mice. Finally, pADA significantly reduced adenosine levels in aged lymph nodes, implicating a potential enzymatic-based regulation of GC immunosenescence. Together, these findings identify ADA as a metabolic adjuvant capable of reversing key features of vaccine immunosenescence and highlight adenosine-dependent CXCR4 regulation as a tractable axis for improving vaccine efficacy in older populations.
    Keywords:   Clostridioides difficile ; Adenosine Deaminase (ADA); Aging; Humoral immunity; Immunosenescence; T follicular helper (TFH) cell; Vaccine adjuvant
    DOI:  https://doi.org/10.1007/s11357-026-02605-0
  15. Proc Natl Acad Sci U S A. 2026 Nov 24. 123(47): e2623940123
      The efficacy of adoptive cell therapies depends on the presence of T cells with durable self-renewal, proliferative capacity, and differentiation potential, yet heterogeneity within starting cell populations remains a major barrier to consistent clinical outcomes. Here, we identify CD49f as a marker of a unique subset of human memory T cells with stem-like characteristics. CD49fHi memory CD8+ and CD4+ T cells exhibited transcriptional and phenotypic features associated with T cell stemness, including elevated LEF1, TCF1, CCR7, CD27, and CD28, while CD49fLo cells exhibited effector-like transcriptional programs. Clinical evaluation of solid-organ transplant recipients treated with virus-specific T cells for cytomegalovirus complications demonstrated that autologous T cell therapies manufactured from CD49fHi-enriched T cells were associated with superior immune reconstitution and greater in vivo expansion of CMV-specific T cells. Functional assays further revealed that CD49fHi memory T cells possessed enhanced proliferative capacity and transcriptional plasticity following activation. Consistent with these findings, CD19 CAR T cells engineered from CD49fHi memory T cells demonstrated improved persistence and conferred superior survival in a preclinical lymphoma model. Together, these findings establish CD49f as a marker of a stem-like memory T cell subset with enhanced therapeutic potential and identify CD49fHi enrichment as a practical strategy to improve the consistency, durability, and clinical efficacy of both virus-specific and CAR T cell therapies.
    Keywords:  CD49f; T cells; immunotherapy; stem-Like; stem-like
    DOI:  https://doi.org/10.1073/pnas.2623940123
  16. Redox Biol. 2026 Nov 16. pii: S2213-2317(26)00488-X. [Epub ahead of print]98 104489
      PIKFYVE, a lipid kinase that generates the endolysosomal phosphoinositide PI(3,5)P2, has emerged as a regulator of Th17 lineage commitment, but how lysosomal phosphoinositide signaling relates to mitochondrial redox homeostasis and T cell epigenetic programming is unknown. Using quantitative proteomics and pharmacological PIKFYVE inhibition with apilimod in Th17-polarized CD4+ T cells, we found that PIKFYVE inhibition reduced IL-17+ cells and increased Foxp3+ cell generation, accompanied by changes in lysosomal, mitochondrial, and redox homeostasis. Proteomics showed higher levels of endolysosomal trafficking, lysosomal acidification, and autophagy proteins and lower levels of glycolytic enzymes. PIKFYVE inhibition lowered the mitochondrial fusion proteins OPA1 and MFN2 and raised respiratory-chain protein content, oxygen consumption, mitochondrial membrane potential, and mitochondrial reactive oxygen species (ROS), whereas intracellular ATP was lower. Lysosomal enlargement, higher LC3-II and p62, and lower PINK1 and Parkin suggest impaired organelle turnover that may contribute to the retention of hyperpolarized mitochondria. Higher ROS coincided with lower ATP citrate lyase (ACLY) abundance, less non-oxidized ACLY and STAT3, lower expression of Th17-associated genes, and reduced H3K27 acetylation, which N-acetylcysteine (NAC) partially restored. NAC strongly reduced Foxp3+ cell generation, including the increase induced by PIKFYVE inhibition. Similar mitochondrial, lysosomal, and redox changes were detected in CD4+ T cells from mice with experimental autoimmune encephalomyelitis (EAE), supporting their in vivo relevance. These findings associate PIKFYVE inhibition with altered lysosomal, mitochondrial, and redox homeostasis and a shift from Th17 toward regulatory T (Treg) cells.
    Keywords:  ACLY; Histone acetylation; PIKFYVE; Reactive oxygen species; STAT3 oxidation; Th17 differentiation
    DOI:  https://doi.org/10.1016/j.redox.2026.104489
  17. Cancer Immunol Res. 2026 Nov 17.
      Accessing tumor-reactive CD8⁺ T cells in patient blood is essential for non-invasive monitoring of systemic T cell responses and guiding personalized therapies. However, precise functional, molecular, and phenotypic characterization of these cells remains challenging. Here, we identify TIGIT as a functionally validated surrogate marker of tumor-reactive CD8⁺ T cells and define its associated transcriptional program to characterize circulating tumor-reactive CD8⁺ T cells in melanoma patients. We demonstrate that blood TIGIT⁺ CD8⁺ T cells mount robust cytotoxic responses against autologous tumor cells across multiple melanoma patient models, irrespective of PD-1 co-expression. At the clonotype level, TIGIT broadened detection of the circulating tumor-reactive repertoire beyond PD-1 while retaining high specificity. Moreover, circulating TIGIT⁺ CD8⁺ T cell population was closely associated with the intratumoral T cell repertoire and exhibited hallmarks of antigen experience, including effector memory differentiation, a hypomethylated DNA landscape, and increased clonal expansion. Longitudinal profiling of blood samples from melanoma patients undergoing immune checkpoint inhibition revealed an increased frequency of TIGIT⁺ CD8⁺ T cells in clinical responders. Finally, leveraging paired single-cell transcriptomic and TCR data from patient models with identified tumor-reactive clones, we show that the TIGIT-associated transcriptional program enables robust detection of circulating tumor-reactive CD8⁺ T cells. Collectively, our data establish TIGIT⁺ CD8⁺ T cells as a potent reservoir of tumor-reactive T cells in peripheral blood and provide a blood-based framework for accelerating TCR discovery and advancing adoptive cell therapy.
    DOI:  https://doi.org/10.1158/2326-6066.CIR-26-0327
  18. bioRxiv. 2026 Nov 10. pii: 2026.11.09.765236. [Epub ahead of print]
      The presence of polyfunctional T cells capable of concurrently producing multiple cytokines correlates with favorable clinical outcomes in patients with cancer. We previously reported that overexpression of constitutively active Stat5a (CASTAT5) confers polyfunctionality on tumor-specific CD4⁺ T cells, enabling durable antitumor immunity following adoptive cell therapy. However, the mechanisms underlying the enhanced antitumor effects of CASTAT5-modified T cells remain unclear. Here, we identify interleukin-13 (IL13) as a critical effector cytokine contributing to the multifaceted antitumor activity of CASTAT5-conditioned polyfunctional CD4⁺ T cells (C5-CD4). C5-CD4 T cells exhibit a prominent T helper 2 (Th2) cytokine profile, accompanied by extensive epigenomic remodeling at the Th2 cytokine loci, as revealed by Hi-C and histone-modification CUT&Tag assays. Neutralization of IL13 diminished the antitumor efficacy of C5-CD4 T cells. Furthermore, targeted Il13 disruption substantially impaired tumor control and was associated with reduced donor T cell expansion and persistence, diminished systemic cytokine and chemokine responses, and attenuated activation of endogenous tumor-reactive CD8⁺ T cells. Nonetheless, IL13 overexpression alone in donor CD4⁺ T cells failed to fully recapitulate the therapeutic activity of C5-CD4 T cells, indicating that IL13 is a critical contributor but is insufficient to account for the full antitumor activity conferred by CASTAT5. Single-cell RNA sequencing associated donor-derived IL13 with increased representation of tumor-infiltrating myeloid cells and IL13-signaling in monocytes and macrophages exhibiting tissue-repair-associated transcriptional programs. Moreover, Il13 disruption diminished the therapeutic efficacy of CASTAT5-expressing CD19-targeted CAR-T cells in a mouse B-cell lymphoma model. Reanalysis of a human CD19CAR-T infusion-product dataset further revealed an association between IL13 expression and type 2 cytokine signatures linked to prolonged clinical response, suggesting a potential contribution of IL13 to the efficacy of human CD19CAR-T therapy. Together, these findings uncover an unexpected antitumor role for IL13 and establish it as a critical node linking polyfunctional donor T cells with endogenous immune cells to promote sustained tumor immunity.
    DOI:  https://doi.org/10.64898/2026.11.09.765236
  19. J Clin Invest. 2026 Nov 16. pii: e204657. [Epub ahead of print]136(22):
      T cell engagers (TCEs) have achieved transformative success in B cell malignancies but show limited efficacy in solid tumors with severe toxicity. We propose that TCR signaling without IL-2 might limit the function of tumor-infiltrating lymphocytes (TILs). Here, we showed that insufficient IL-2 signaling is a key bottleneck for sustaining TCE-induced T cell function. Although exogenous IL-2 enhances TCE efficacy, its systemic administration causes more severe toxicity. We engineered a protease-activatable dual-variable domain (DVD) as a pro-antibody to reduce αCD3 off-tumor toxicity. Furthermore, we designed 3 additional mutations for IL-2 (3E) with markedly reduced receptor affinity, which remained inactive in the periphery. By coengineering the DVD and 3E into a single pro-drug molecule (DVD-3E), we achieved conditional IL-2 and TCR cosignaling strictly dependent on cis CD3 engagement within the tumor microenvironment (TME) upon protease cleavage. This logic-gated design restricted both TCE and cytokine activity to the TME, enabling potent antitumor responses without systemic toxicity. Mechanistically, DVD-3E enhanced not only the persistence and effector function of preexisting intratumoral T cells but also expanded TCF1+ TILs, mitigating exhaustion and enabling durable systemic immunity. These findings define a new design principle for logic-gated TCEs that achieve a favorable balance between efficacy and safety, offering a strategy to overcome current therapeutic resistance.
    Keywords:  Cytokines; Drug therapy; Immunology; Oncology; T cells
    DOI:  https://doi.org/10.1172/JCI204657
  20. Exp Hematol Oncol. 2026 Nov 20. pii: 128. [Epub ahead of print]15(1):
      Immune cell plasticity is a defining feature of tumor immunity and is increasingly recognized as being governed by epigenetic regulation. Advances in single-cell and spatial multi-omics have uncovered an epigenetic checkpoint that integrates environmental cues within the tumor microenvironment (TME) to shape immune cell fate and function. In this review, we synthesize recent evidence supporting three interconnected paradigms of epigenetic control in tumor immunity from the perspective of immune cell heterogeneity, ecology, and state transitions. First, dynamic chromatin remodeling programs myeloid cell polarization and functional diversification. Second, epitranscriptomic regulation constrains T and B cell states, contributing to immune dysfunction and exhaustion. Third, spatially resolved epigenetic remodeling influences immune cell trafficking, positioning, and retention within tumors. Collectively, these mechanisms establish durable immune states that reinforce TME-driven immunosuppression. We further highlight emerging pharmacological strategies targeting epigenetic regulators to reprogram immune cell function and enhance anti-tumor immunity. This framework provides a foundation for leveraging epigenetic plasticity to improve the efficacy of cancer immunotherapy.
    Keywords:  Adaptive immune cell; Anti-tumor immunity; DNA methylation; Epigenetic regulation; Histone modification; Immuno-oncology; Innate immune cell
    DOI:  https://doi.org/10.1186/s40164-026-00856-3
  21. Front Immunol. 2026 ;17 1996492
      Consider what the T-cell compartment accomplishes. For decades it sustains immune competence while the thymus shrinks, antigens accumulate, and tissues change around it. We propose that this longevity rests on four coupled capacities: input renewal, repertoire maintenance and clonal dynamics, lineage-constrained plasticity, and tissue-contextual fitness. Input renewal is treated as a proxy domain inferred from calibrated peripheral correlates, not as a direct measure of thymic flux. Our claim is simple: these capacities need not age in concert, whether one compares individuals, tissues, or challenges. The biology behind them is well known. Thymic involution restricts the entry of naive T cells, antigen history reshapes the T-cell receptor (TCR) repertoire, metabolic and epigenetic changes erode proliferative reserve, and aged tissue niches alter survival, trafficking, and local function. Nevertheless, some individuals retain protective responses in particular subsets and tissues, a pattern consistent with compensation during aging and exceptional longevity. We introduce renewable potential as a broader concept than T-cell stemness and distinguish terminal differentiation from exhaustion and senescence-like phenotypes. We then consider how longitudinal turnover measurements, clone-aware analyses, and perturbation studies can move the field beyond cross-sectional, age-associated signatures. Its predictions are concrete: capacities may disagree within a person, compartments may age at different rates, the limiting capacity may depend on context, compensation may give way to maladaptive fixation, and intervention responses may vary with the baseline capacity profile. Vaccination and infection, cancer, transplantation, autoimmunity, and tissue inflammation illustrate these constraints. On this view, the T-cell immune-longevity capacity profile describes a context-dependent pattern of deficits and compensations, not a universal immune-age score or a proxy for chronological age.
    Keywords:  T-cell aging; T-cell stemness; TCR repertoire; capacity profiling; immune longevity; immunosenescence; renewal dynamics; systems immunology
    DOI:  https://doi.org/10.3389/fimmu.2026.1996492
  22. Front Immunol. 2026 ;17 1940192
       Background: Galectin-3 (Gal-3) is a multifunctional β-galactoside-binding lectin implicated in immune regulation, yet its association with T cell phenotypes under physiological and inflammatory conditions remains incompletely defined.
    Methods: We investigated Gal-3 expression and binding on murine and human T cells across developmental stages, tissues, sex, genetic background, circadian time, and inflammatory disease settings.
    Results: In mice, Gal-3-associated CD4+ and CD8+ T cells were dynamically regulated by age, anatomical location, strain, sex, and circadian rhythm. Gal-3+ T cells displayed increased activation markers, enhanced TCR-associated signaling molecules, elevated cytolytic mediators, increased proliferation, and greater apoptosis. Gal-3+ T cells were enriched within central and effector memory compartments and expressed higher levels of co-inhibitory receptors, including PD-1, with ImageStream analysis confirming Gal-3 co-expressed with PD-1. Recombinant Gal-3 preferentially bound activated, but not resting T cells, and associated with CD44 and CD3, suggesting activation-dependent acquisition of extracellular Gal-3. Re-analysis of human thymocyte and Long COVID single-cell RNA-seq datasets further supported an association between LGALS3 expression and activated/exhausted T cell states. Finally, intracellular staining indicated that T cells are unlikely to be a major source of Gal-3.
    Conclusion: Our findings identify Gal-3 as a context-dependent marker and potential regulator of activated, antigen-experienced T cells, which promotes T cell apoptosis.
    Keywords:  CD11b; CD44; PD-1; TCR; co-inhibitory receptors; thymocytes
    DOI:  https://doi.org/10.3389/fimmu.2026.1940192
  23. J Immunother Cancer. 2026 Nov 16. pii: e016004. [Epub ahead of print]14(11):
      
    Keywords:  Immunotherapy; Skin Cancer; Solid tumor; Tumor infiltrating lymphocyte - TIL
    DOI:  https://doi.org/10.1136/jitc-2026-016004
  24. Front Immunol. 2026 ;17 1961624
      Sepsis is a life-threatening systemic inflammatory response syndrome triggered by infection, characterized by profound dysregulation of the immune system. Dendritic cells (DCs), which serve as the essential bridge between innate and adaptive immunity, play a critical role in the pathogenesis and progression of sepsis. The functional status of DCs profoundly influences the activation, differentiation, and function of T cells, thereby determining disease outcomes. This review systematically summarizes the dynamic changes in the developmental lineage and functional phenotype of DCs in the context of sepsis, as well as their multi-layered regulatory mechanisms governing T cell responses. We focus on the molecular basis of sepsis-induced DC dysfunction-including apoptosis, exhaustion, and immunoparalysis-and the resulting T cell immunosuppression. Finally, we discuss current progress in intervention strategies aimed at restoring T cell immune homeostasis by modulating DC function, providing a theoretical foundation for understanding the immunopathology of sepsis and developing novel immunotherapies.
    Keywords:  T cells; dendritic cells; immune regulation; immunosuppression; immunotherapy; sepsis
    DOI:  https://doi.org/10.3389/fimmu.2026.1961624
  25. J Inflamm (Lond). 2026 Aug 24. pii: 28. [Epub ahead of print]23(1):
       BACKGROUND: Mitochondria serve as central regulators of cellular bioenergetics and inflammatory signaling, integrating metabolic status with immune responses. Disruption of mitochondrial homeostasis, including altered tricarboxylic acid cycle dynamics, redox imbalance, and aberrant reactive oxygen species production, contributes to persistent inflammation and disease pathogenesis. Among emerging mitochondrial immunometabolic regulators, the IRG1/ACOD1-derived metabolite itaconate has gained attention as a critical molecular integrator linking mitochondrial metabolism to inflammatory control.
    MAIN BODY: This review systematically summarizes the biosynthesis of itaconate and its role in mitochondrial metabolic remodeling during inflammation. Itaconate reshapes the tricarboxylic acid cycle and inhibits succinate dehydrogenase, thereby limiting mitochondrial reactive oxygen species generation and preventing amplification of pro-inflammatory signaling. Through covalent modification of KEAP1, it activates the NRF2 antioxidant program, while concurrently restraining NLRP3 inflammasome activation, establishing a mitochondrial metabolic checkpoint that constrains excessive immune activation. Beyond acute metabolic regulation, itaconate coordinates sustained immunoregulatory programs via the ATF3-IκBζ transcriptional axis, autophagy-lysosome system modulation, and epigenetic reprogramming. We further integrate cell-type-specific effects of itaconate across macrophages, dendritic cells, T cells, and neutrophils, and discuss how mitochondrial immunometabolic dysregulation contributes to chronic inflammatory and metabolic disorders.
    CONCLUSION: By positioning the IRG1-itaconate axis within the broader framework of mitochondrial immunometabolism, this review highlights mitochondria as a central hub linking metabolic remodeling with inflammatory regulation. Targeting mitochondrial metabolic checkpoints such as the itaconate pathway may provide promising therapeutic strategies for restoring immune homeostasis and treating inflammation-associated diseases.
    DOI:  https://doi.org/10.1186/s12950-026-00510-z
  26. Curr Opin HIV AIDS. 2026 Nov 17.
       BACKGROUND: Despite the exceptional clinical results of antiretroviral therapy (ART) in reducing morbidity and mortality, HIV infection cannot be cured due to a pool of infected cells, mainly memory CD4 + T cells, that is established within weeks of initial infection and persists under ART; this virus reservoir causes rapid rebound of viral replication if ART is stopped.
    RECENT FINDINGS: The preclinical animal model of simian immunodeficiency virus (SIV) infection in rhesus macaques (RMs) recapitulates key features of HIV infection, pathogenesis, immunology, and persistence in humans, including early establishment and long-term survival of the virus reservoir and rapid viral recrudescence after ART interruption. The SIV infection model is fundamental for investigating biological mechanisms that, when specifically targeted, may reduce and eliminate the reservoir pool.
    PURPOSE OF REVIEW: The goal of this review is not to provide an overview of the most recent findings in HIV persistence. Instead, it focuses on three biological mechanisms of viral persistence that our team of investigators, as well as others in the field, have described and for which we are testing innovative targeted interventions to: preferentially kill infected CD4 + memory T cells by targeting intracellular mechanisms favoring their survival; induce a stronger and durable cytolytic response by CD8 + T cells, and eliminate the CD8 + T cell remodeling of CD4 + T cell metabolism that promotes viral latency.
    Keywords:  Bcl-2; CD8 cells; CTL; noncytolytic; viral reservoir; virus silencing
    DOI:  https://doi.org/10.1097/COH.0000000000001096
  27. Commun Med (Lond). 2026 Jul 28. pii: 595. [Epub ahead of print]6(1):
       BACKGROUND: The abscopal effect, in which radiotherapy of one tumor is associated with regression of distant non-irradiated tumors, remains uncommon even when combined with immune checkpoint blockade. Although systemic T cell priming is required, the mechanisms that determine whether effector T cells persist within distant tumors remain unclear. We investigated whether SFRP2-expressing stromal cells limit CD8+ T cell stress resilience in abscopal tumors.
    METHODS: We used bilateral mouse tumor models treated with fractionated radiotherapy plus anti-PD-1 antibody, combined with immune profiling of irradiated tumors, tumor-draining lymph nodes, and distant tumors. Human lung cancer specimens, public transcriptomic datasets, fibroblast-specific Sfrp2 deletion, single-cell RNA sequencing, immunostaining, flow cytometry, and fibroblast-T cell co-culture assays were used to examine the relationship between SFRP2, CD8+ T cell apoptosis, and stress-response signaling. Statistical analyses included two-sided tests and multiple-comparison correction where appropriate.
    RESULTS: Here we show that radioimmunotherapy activates local tumor immunity and tumor-draining lymph node priming, but resistant distant tumors fail to maintain CD8+ T cell accumulation. SFRP2 is enriched in fibroblast-like stromal compartments and is inversely associated with CD8+ T cell infiltration. Fibroblast-specific Sfrp2 deletion reduces CD8+ T cell apoptosis and restores an HSPA1A/HSP70-associated stress-resilience program. Mechanistically, SFRP2 suppresses a WNT-HSF1-HSPA1A signaling program, whereas Hspa1a overexpression reduces SFRP2-associated caspase-3 activation in T cells.
    CONCLUSIONS: These findings identify stromal suppression of CD8+ T cell stress resilience as a mechanism of abscopal resistance and support SFRP2-WNT-HSF1 pathway targeting as a potential strategy to improve radioimmunotherapy.
    DOI:  https://doi.org/10.1038/s43856-026-01829-7
  28. Immunohorizons. 2026 Nov 05. pii: vlag062. [Epub ahead of print]10(11):
      T helper 17 (Th17) CD4+ T cells are key mediators of autoimmune pathology. Interleukin (IL)-1β is a potent proinflammatory cytokine known to promote Th17 differentiation and pathogenicity, in combination with other cytokines. Whereas recent studies have shown that T cells are capable of expressing IL-1β themselves, the role of this T cell-endogenous IL-1β is poorly understood. Using CRISPR/Cas9-mediated deletion of IL1B in naïve human CD4+ T cells along with cytokine neutralization and IL-1 receptor blockade, we found that T cell-intrinsic IL-1β is not essential for Th17 differentiation or effector resistance. Remarkably, single-cell RNA sequencing revealed that IL1B deletion profoundly rewires the transcriptional and metabolic landscape within the T cells, suppressing glycolytic and hypoxia-responsive pathways. These findings uncouple T cell-intrinsic IL-1β from Th17 effector resistance while uncovering an important contribution toward sustaining metabolic roles. This refines our understanding of IL-1β biology and informs therapeutic strategies in immune-mediated disease settings.
    Keywords:  CD4 T cells; IL-1β; Th17 cells; autoimmune disease; single cell RNA transcriptomics
    DOI:  https://doi.org/10.1093/immhor/vlag062
  29. bioRxiv. 2026 Nov 14. pii: 2026.09.18.752798. [Epub ahead of print]
      Isocitrate dehydrogenase (IDH) is the most frequently mutated metabolic enzyme in human cancers. Mutant IDH produces D-2-hydroxyglutarate (D-2HG), which promotes tumorigenesis through epigenetic alterations. Beyond cell-autonomous effects, tumor-derived D-2HG acts as a potent immunosuppressant that establishes an immune-cold tumor microenvironment (TME). However, the mechanism by which D-2HG is released from tumors remains largely unknown. Here, we identify the SWELL1 (LRRC8A)/LRRC8C-containing volume-regulated anion channel (VRAC) as a principal pathway for D-2HG efflux from IDH-mutant cells. Deletion of SWELL1, the essential VRAC subunit, markedly reduces D-2HG release and reverses associated immunosuppression in an orthotopic mouse model of IDH-mutant glioma. Strikingly, VRAC loss causes intracellular D-2HG accumulation, which paradoxically limits glioma proliferation by driving epigenetic remodeling and mitochondrial metabolic stress. Pharmacological VRAC inhibition with dicumarol suppresses IDH-mutant glioma growth, enhances intratumoral T cell activation, synergizes with immune checkpoint blockade, and prolongs survival in tumor-bearing mice. In human IDH-mutant lower-grade gliomas, elevated LRRC8C expression correlates inversely with DNA hypermethylation and positively with an immunosuppressive TME, and is associated with poor survival. Together, these findings establish VRAC-mediated D-2HG export as a previously unrecognized D-2HG clearance pathway that promotes both immune evasion and tumor cell fitness, uncovering new therapeutic opportunities beyond direct inhibition of D-2HG synthesis.
    DOI:  https://doi.org/10.64898/2026.09.18.752798
  30. bioRxiv. 2026 Nov 10. pii: 2026.06.08.730600. [Epub ahead of print]
      Identifying interventions that improve health and cardiac function is important for extending healthspan. We show that supplementation with the SCFA butyrate beginning at 18 months (late life) extends survival in male and female mice and improves systemic metabolic and physical-performance measures. Treatment reduces adiposity and fasting glucose and attenuates age-associated cardiac hypertrophy, fibrosis, and systolic and diastolic dysfunction. Integrated plasma and myocardial metabolomics and lipidomics reveal compartment-dependent metabolic remodeling, while cardiac proteomics and full-length RNA sequencing identify coordinated changes in extracellular-matrix, RNA-processing, lipid-metabolism, and autophagy-associated programs. These molecular responses are accompanied by improved mitochondrial ultrastructural organization and respiratory function. Butyrate supplementation also enhanced cardiac autophagy and mitophagy, and its beneficial effects on LV hypertrophy and diastolic indices required ATG7. These findings demonstrate that butyrate supplementation initiated at an advanced age modifies systemic and cardiac aging phenotypes and implicate metabolic remodeling and mitochondrial quality control pathways as contributing to these benefits.
    Graphical abstract:
    DOI:  https://doi.org/10.64898/2026.06.08.730600
  31. Cancer Immunol Res. 2026 Nov 19.
      CAR-T cells have yet to show widespread efficacy in solid tumors due in part to poor persistence and dysfunction in the tumor microenvironment. Further, heterogenous expression of target antigens can lead to escape of antigen-null tumors that resist CAR-T killing. Strategies to cooperatively boost both CAR-T and endogenous antitumor immunity may be critical for achieving durable efficacy in cancer patients. NKTR-255 is a polymer-conjugated IL-15 with extended half-life that can boost endogenous T and NK cells, as well as CD19 CAR-T cells in B cell malignancies. However, whether NKTR-255 is sufficient to overcome CAR-T dysfunction in the suppressive solid tumor microenvironment, and how NKTR-255 and CAR-Ts together re-shape endogenous antitumor immunity, is not known. Using mouse models of ROR1+ lung adenocarcinoma, we show that NKTR-255 significantly boosted accumulation and function of tumor-infiltrating CAR-T cells targeting ROR1. Compared with NKTR-255 or CAR-T treatment alone, combination of NKTR-255 and CAR-T therapy increased endogenous tumor-specific T cells that preserved a PD-1+Tcf1+ stem-like phenotype. Consequently, NKTR-255 and CAR-T combination therapy completely eliminated ROR1+ tumor cells and significantly improved survival, with enhanced tumor control dependent on both CAR-Ts and endogenous T cells, though all mice ultimately succumbed to progression of ROR1- tumor. Compared to IL-15-armored CAR-T cells, systemic NKTR-255 induced greater accumulation and reduced terminal differentiation of endogenous tumor-specific T cells, resulting in superior tumor control. Thus, combining NKTR-255 with CAR-T therapy is a promising strategy to enhance both CAR-T and endogenous antitumor immunity to promote coordinated control of aggressive tumors.
    DOI:  https://doi.org/10.1158/2326-6066.CIR-25-1569
  32. Front Oncol. 2026 ;16 1993212
      Metabolic reprogramming is one of the core hallmarks of malignant tumors, among which the abnormally enhanced glycolysis driven by the Warburg effect constitutes a critical aspect of tumor metabolic remodeling. LDHA is abnormally highly expressed in various tumors, and its expression level is closely related to tumor malignancy. The high expression of LDHA is not limited to overall elevation but also exhibits spatial heterogeneity. LDHA expression is significantly higher in highly invasive tumor edge regions compared to low-invasive regions. LDHA maintains high glycolytic flux by catalyzing the conversion of pyruvate to lactate while regenerating NAD+, rapidly producing ATP to meet the energy demands of rapid tumor cell proliferation. Lactate produced through high glycolytic flux can be taken up by cancer-associated fibroblasts (CAFs) via MCT1 and enter the tricarboxylic acid cycle, promoting CAF proliferation. LDHA expression levels are positively and significantly correlated with intracellular lactate concentrations, and lactate, as the direct substrate source for histone lactylation modifications, changes in its abundance directly regulate histone lactylation levels. Lactate acts as an alternative energy substrate, providing fuel for oxidative tumor cells or tumor-associated stromal cells via monocarboxylate transporter (MCT1/4)-mediated lactate shuttle, forming a metabolic symbiosis network. The acidification of the tumor microenvironment, directly inhibiting T cell function, promoting T cell differentiation toward regulatory T cells, upregulating the expression of inhibitory receptors on the T cell surface to induce T cell exhaustion, and interfering with the formation of memory T cells. It also promotes macrophage polarization from the pro-inflammatory M1 type to the immunosuppressive M2 type, enhancing their tumor-promoting growth, angiogenesis, and tissue remodeling functions. Currently, LDHA inhibitors (e.g., FX-11 and GSK2837808A) and MCT1 inhibitors (e.g., AZD3965) have shown preclinical potential in suppressing tumor growth, reversing immunosuppression, and sensitizing conventional therapies. Some of these agents have already advanced into early-stage clinical trials. However, this strategy still faces challenges including enhanced tumor metabolic plasticity, on-target toxicity, and a lack of predictive biomarkers. Future research should focus on optimizing combination therapy strategies, elucidating mechanisms of metabolic adaptation, and enabling precise patient selection, thereby advancing novel therapeutic approaches based on lactate metabolism intervention toward clinical translation.
    Keywords:  LDHA; Warburg effect; lactate; metabolic reprogramming; tumor microenvironment
    DOI:  https://doi.org/10.3389/fonc.2026.1993212
  33. Cancer Lett. 2026 Nov 16. pii: S0304-3835(26)00739-1. [Epub ahead of print] 218975
      CD8 T cells can make a decisive contribution to anticancer immune responses. While the glycoprotein CD101 is present on effector CD8 T cells, the signaling pathways driving CD101 expression and the outcome of CD101 engagement on CD8 T cells are elusive. Here, we show that the activation of TGF-β signaling induces CD101 on mouse and human CD8 T cells. CD101 expression on CD8 T cells was dependent on TCR signaling and TGF-β-induced Smad3. In multiple cancers, we found that mouse and human CD8(+) CD101(+) tumor infiltrating lymphocytes exhibited a resident memory phenotype, as illustrated by co-expression of CD69 and CD103. Accordingly, CD101-deficient mice featured accelerated tumor growth and were unable to respond to anti-PD-1 therapy. Altogether, these results suggest that CD101 expression on CD8 T cells has functional relevance and can be therapeutically exploited for anticancer therapy.
    Keywords:  Adaptive immunity; T cells; cancer; immunomodulation; immunotherapy
    DOI:  https://doi.org/10.1016/j.canlet.2026.218975
  34. Mol Ther Oncol. 2026 Dec 17. 34(4): 201368
      Chimeric antigen receptor (CAR)-T cell therapy has achieved remarkable success in the treatment of hematologic malignancies. However, increasing clinical experience has highlighted the need for further improvement in its therapeutic efficacy, particularly in terms of durable clinical responses. The costimulatory domain is a critical component of CAR design, essential for promoting anti-tumor activity and T cell persistence. The choice of costimulatory domain can significantly influence CAR-T cell function and differentiation, thereby impacting clinical outcomes. In this study, we identified an intracellular motif derived from human CD26 that functions as a costimulatory domain. Incorporation of the CD26 cytoplasmic domain into CD3ζ CARs enhanced T cell functionality and mitigated exhaustion. Compared to the conventional costimulatory domain, the CD26-based CAR demonstrated a more favorable exhaustion profile than CD28 and achieved comparable anti-tumor efficacy to 4-1BB. Under repetitive antigen stimulation, incorporation of the CD26 module into CD28ζ CARs reduced the exhaustion phenotype and preserved cytotoxic activity. These findings position CD26 as a promising and versatile complementary costimulatory module for next-generation CAR designs, offering new opportunities to optimize CAR-T cell performance, particularly in challenging tumor microenvironments.
    Keywords:  CAR-T cell therapy; CD26; T cell exhaustion; costimulatory domain; immunotherapy
    DOI:  https://doi.org/10.1016/j.omton.2026.201368
  35. Cell Rep. 2026 Nov 13. pii: S2211-1247(26)01371-9. [Epub ahead of print]45(11): 118292
      The antiviral CD8 T cell response is critical for controlling viral infections, including SARS-CoV-2. Spike mutations can mediate escape from pre-existing T cell immunity but it remains unclear whether such variants induce variant-specific CD8 T cells. Here, we investigate the HLA-A⁎24:02-restricted immunodominant NF9/A24 epitope (S448-456) and its prevalent L452R variant (NF9-5R) in Omicron BA.5 convalescents. NF9-5R-specific CD8 T cells are not detected ex vivo or after short-term in vitro stimulation of PBMCs, despite robust responses to other epitopes. In HLA-A24 transgenic mice, NF9 is markedly more immunogenic than NF9-5R, with rare cross-reactive responses. However, in vitro priming of NF9-5R-reactive CD8 T cells enables identification of a cross-reactive TCR (12E) recognizing both peptides and cells expressing spike L452R. Although the NF9-5R peptide can thus be presented and recognized, escape at an immunodominant epitope is not compensated by variant-specific CD8 T cells in vivo, creating functional "blind spots" relevant to vaccine strategies.
    Keywords:  CD8 T cells; COVID-19; CP: immunology; HLA-A(⁎)24:02; SARS-CoV-2; T cell receptor; TCR repertoire; cross-reactivity; immune escape; immunodominance
    DOI:  https://doi.org/10.1016/j.celrep.2026.118292
  36. bioRxiv. 2026 Nov 09. pii: 2026.11.05.764445. [Epub ahead of print]
      Aging is a major risk factors for metabolic dysfunction-associated steatotic liver disease (MASLD). However, the mechanisms by which aging disrupts hepatocyte transcriptional networks to drive metabolic dysfunction remain poorly understood. Hepatocyte nuclear factor 4 alpha (HNF4α) is a master regulator of hepatocyte identity and metabolic homeostasis, but its role in liver aging has not been defined. Here, we perform a comprehensive multi-omic profiling of young and aged mouse livers combined with targeted HNF4α functional studies to define how aging remodels HNF4α-dependent gene regulation and whether HNF4α can be a target to reverse age-associated liver dysfunction. Despite preserved HNF4α expression with age, aging was associated with reduced HNF4α chromatin occupancy and transcriptional activity, accompanied by epigenetic remodeling, including changes in histone acetylation, chromatin accessibility, and DNA methylation. Integration and comparison of HNF4α CUT&RUN with hepatocyte-specific Hnf4a deletion in young and aged livers identified high-confidence overlapping but distinct young- and old-specific HNF4α target gene networks. In young hepatocytes, HNF4α coordinates two complementary transcriptional programs: activation of genes governing hepatocyte identity, lipid metabolism, and metabolic function, while simultaneously inhibiting alternative developmental, proliferative, and inflammatory programs. Spatial transcriptomic analyses further revealed zone-specific specialization of HNF4α-dependent gene programs. Aging selectively disrupted these regulatory networks, resulting in compromised liver identity and metabolic gene programs, de-repression of inflammatory pathways and alternative cellular identity programs and disrupted hepatocyte zonation, consistent with age-dependent lipidomic and metabolic changes, hepatic fat accumulation, and immune infiltration. Hepatocyte-specific Hnf4a deletion in young mice recapitulated key features of liver aging, including impaired hepatocyte identity, metabolic dysfunction, steatosis, inflammatory activation and altered hepatic immune-cell composition, while deletion in aged mice further exacerbated steatosis, inflammation, and hepatic dysfunction. Conversely, hepatocyte-specific HNF4α restoration in aged mice significantly reduced hepatic steatosis and lipid accumulation, restored fatty acid metabolic programs, and partially reversed age-associated transcriptional changes. However, inflammatory and interferon-associated programs were not uniformly reversed, revealing differential responsiveness of metabolic and inflammatory pathways to HNF4α restoration. Together, these findings identify age-associated impairment of HNF4α activity as a functional contributor to liver aging, linking dysregulation of hepatocyte identity, metabolic homeostasis, and inflammatory control to age-associated hepatic dysfunction. Importantly, the selective reversibility of metabolic defects following HNF4α restoration establishes HNF4α as a promising strategy for preserving hepatocyte homeostasis and reversing age-associated hepatic metabolic dysfunction.
    DOI:  https://doi.org/10.64898/2026.11.05.764445
  37. Blood Red Cells Iron. 2026 Sep;2(3): 100091
      Sickle cell disease (SCD) is characterized by chronic hemolysis and excess free heme, which drive oxidative stress, inflammation, and progressive organ damage. Although the pathological consequences of heme are well recognized, its direct impact on erythroid metabolism and epigenetic regulation remains incompletely understood. Here, we demonstrate that excess heme acts as a central metabolic-epigenetic disruptor in sickle erythroblasts, triggering ferroptosis through coordinated suppression of glutamine metabolism and mitochondrial function. Hemin exposure induced robust lipid peroxidation and ferroptotic cell death, accompanied by impaired cystine uptake, glutathione depletion, and increased ferroptosis markers. Mechanistically, heme selectively repressed the catalytically active glutaminase (GLS) isoform GLS type C, leading to reduced intracellular glutamate availability and compromised redox homeostasis. At the epigenetic level, heme promoted global histone hypermethylation and chromatin compaction at genes governing glutamine and glutamate metabolism. This effect was driven by mitochondrial dysfunction and disruption of the oxoglutarate dehydrogenase complex, resulting in the accumulation of l-2-hydroxyglutarate, a potent inhibitor of α-ketoglutarate-dependent histone demethylases. Stable isotope tracing confirmed enhanced glutamine flux toward 2-oxoglutarate and l-2-hydroxyglutarate under heme stress. Importantly, supplementation with the cell-permeable α-ketoglutarate analog dimethyl α-ketoglutarate restored tricarboxylic acid cycle activity, reduced histone hypermethylation, rescued GLS expression, replenished glutathione, and alleviated heme-induced ferroptosis. Together, these findings uncover a previously unrecognized metabolic-epigenetic circuit linking excess heme to mitochondrial dysfunction, chromatin remodeling, and ferroptosis in sickle erythropoiesis and identify metabolic repletion strategies as potential therapeutic treatment approaches for SCD.
    DOI:  https://doi.org/10.1016/j.brci.2026.100091
  38. ACS Med Chem Lett. 2026 Nov 12. 17(11): 2434-2442
      Butyrophilin 3A3 (BTN3A3) senses mevalonate-derived phosphoantigens (pAgs), but its ligand chemistry remains unexplored. We synthesized phosphonate analogs of mevalonate diphosphate (MPP) and evaluated their stimulation of γ9δ2 T cells. Several compounds induced interferon γ production from human effector γ9δ2 T cells, although none potently stimulated naïve-γ9δ2 T cell proliferation. Compound 17 was the most active pAg; it outperformed MPP and preferentially acted in BTN3A3-expressing cells. Compound 17 resisted the lovastatin-mediated pathway blockade and, importantly, synergized with POM2-C-HMBP, a BTN3A1 agonist. These findings identify 17 as a BTN3A3-biased pAg and support chemically tuning mevalonate-derived scaffolds to modulate γ9δ2 T cell responses.
    Keywords:  BTN3A3; butyrophilin; mevalonate diphosphate; phosphoantigen; phosphonate prodrug; γδ T cells
    DOI:  https://doi.org/10.1021/acsmedchemlett.6c00432
  39. Neoplasia. 2026 Nov 10. pii: S1476-5586(26)00130-2. [Epub ahead of print]83 101398
       BACKGROUND: Overcoming the suppressive tumor microenvironment (TME) remains an important unmet challenge for chimeric antigen receptor (CAR)-T cell therapies. Transforming growth factor β (TGFβ) is a key driver of T-cell suppression, reducing T-cell receptor (TCR)-mediated cytotoxicity and driving the differentiation of immunosuppressive regulatory T cells (Tregs) in the TME.
    METHODS: To overcome TGFβ-mediated immunosuppression, we employed a TGFβ-targeting CAR coexpressed with a human papillomavirus type 16 (HPV16) E711-19-specific, HLA-A*02:01-restricted TCR (E7 TCR) in T cells. TGFβ-CAR constructs incorporating either CD28 or 4-1BB costimulatory domains were evaluated for their effects on T-cell function and phenotype.
    RESULTS: Compared with T cells expressing E7 TCR only or E7 TCR with an irrelevant CD19 CAR, T cells co-transduced with E7 TCR and TGFβ-CAR showed enhanced proliferation and cytokine production while maintaining cytotoxicity upon repeated rounds of challenge with HPV16+ Ca Ski tumor cells, which provided a natural source of active TGFβ in coculture. TGFβ-CAR-expressing T cells also exhibited reduced exhaustion-marker expression and Treg differentiation after repeated antigen challenges. Transcriptional analysis further showed reduced FOXP3 expression and enhanced expression of proinflammatory genes including IFNG. In mice bearing B16-F10 tumors, TGFβ-BB-ζ-expressing pmel-1 cells reduced tumor burden and prolonged progression-free survival versus PBS and increased circulating donor T cells versus mock-transduced controls.
    CONCLUSIONS: Together, these data demonstrate that TGFβ-CAR can enhance T-cell effector function while limiting Treg differentiation, supporting its development as a platform to improve the function and persistence of TCR-T cell therapies in suppressive TMEs.
    Keywords:  Adoptive cellular immunotherapy; Chimeric antigen receptor; HPV16; T-cell receptor; Transforming growth factor beta; Tumor microenvironment
    DOI:  https://doi.org/10.1016/j.neo.2026.101398
  40. Front Immunol. 2026 ;17 1960580
       Background: Germline GATA2 deficiency is a hereditary disorder characterized by immunodeficiency, bone marrow failure, and a high risk of myelodysplastic neoplasms and acute myeloid leukemia (AML). Although abnormalities of innate immunity are well recognized, the phenotype and functional state of CD8+ T cells remain incompletely characterized.
    Methods: We performed integrated phenotypic, transcriptional, metabolic, functional, and ultrastructural analyses of peripheral blood cells from six non-transplanted GATA2-deficient patients without ongoing AML, combining CD8+ T-cell-specific immunophenotyping and mass cytometry with bulk cytokine-induced killer (CIK) differentiation and complementary metabolic and mitochondrial assays. We additionally performed single-cell transcriptomic analysis of a previously published gata2b+/- zebrafish model.
    Results: GATA2-deficient CD8+ T cells exhibited contraction of the central memory compartment. Transcriptomic and mass cytometric analyses demonstrated increased activation and cell-cycle programs. Despite preserved short-term cytotoxicity, sustained CIK differentiation was accompanied by metabolic and mitochondrial abnormalities, including lower respiratory reserve at day 6, broader reductions in respiratory parameters by day 14, higher basal extracellular acidification at day 6, increased mitochondrial content with reduced membrane-potential-dependent activity, and mitochondrial ultrastructural remodeling. Increased expression of glycolytic and mitochondrial remodeling-associated proteins supported a coordinated remodeling of metabolic pathways during activation. Similar inflammatory and metabolic transcriptional signatures were identified in gata2b+/- zebrafish T cells, providing supportive cross-species evidence.
    Conclusions: GATA2 deficiency is associated with an activated CD8+ T-cell phenotype accompanied, during sustained CIK differentiation, by progressive metabolic and mitochondrial abnormalities. These findings identify impaired metabolic fitness as a previously underrecognized component of T-cell dysfunction in GATA2 deficiency.
    Keywords:  CD8+ lymphocytes; GATA2 deficiency; T cells; inborn errors of immunity; myelodysplastic syndrome
    DOI:  https://doi.org/10.3389/fimmu.2026.1960580
  41. bioRxiv. 2026 Nov 13. pii: 2026.03.23.713618. [Epub ahead of print]
      Drosophila larval hemocytes, analogous to vertebrate myeloid cells, are central to innate immunity. Despite advances in characterizing hemocyte functions via genetic and biochemical analyses, their metabolic characteristics remain poorly understood. Here, we analyzed metabolic parameters of larval hemocytes across developmental stages, genotypes, and immune activation states using metabolic measurements and single-cell transcriptomics. Our results reveal that hemocytes predominantly rely on mitochondrial respiration for ATP production under homeostasis, with minimal glycolysis. Proliferation or immune activation, particularly lamellocyte differentiation, enhance mitochondrial activity and metabolic flexibility, accompanied by mitochondrial structural remodeling and upregulation of sugar metabolism genes. Functional lamellocytes modulate mitochondrial fission through Drp1 and utilize glucose and trehalose to fuel mitochondrial respiration, which are essential for effective immune responses. Together, these findings provide a comprehensive profile of hemocyte metabolism and highlight the dynamic interplay between mitochondrial metabolism and innate immunity in invertebrate immune cells.
    DOI:  https://doi.org/10.64898/2026.03.23.713618